[ad_1]
A-share “Medical One Brother” was involved in the bribery case, and 7.5 billion academic promotion fees were also questioned! The company’s latest response is coming …
Source: company official micro
Times Sun Xianchao original stock
Recently, a brother of medicine in the A-share marketHengrui Medicine(600276) Involved in a bribery case involving a doctor at a hospital in Zhejiang.
Hengrui Pharmaceutical issued a clarification notice on the night of May 12, saying that some of the witnesses to the hospital’s bribery case in Zhejiang were employees of the company’s subsidiaries. After verification, the incident was a personal behavior of the subsidiary’s employees, which seriously violated the company’s management system, but also reflected a gap in the company’s management. Currently, the relevant staff has left and the responsible leaders of the subsidiaries have been transferred from their posts. The company and its directors, supervisors and senior executives have no violations of laws and regulations, and there is currently no relevant lawsuit. Going forward, the company will learn lessons and strengthen compliance management for its subsidiaries to prevent such incidents from occurring.
According to company e reporters, some media recently published an article titled “Where did Hengrui Medicine spend nearly 7.5 billion yuan a year on academic promotion”? The article says that recently, the criminal sentence of Lei Lipei, director of the anesthesiology department at a hospital in Lishui, Zhejiang province, once again put the discussion in the movie “I am not a drug god” about whether to cure people or save money from patients in the public eye. Looking at the China Rules Document Network, Hengrui Medicine is involved in more than one case of medical corruption.
The article noted that in 2019 Hengrui Medical spent 8.5 billion on selling expenses and questioned the rationality of the company’s 2019 selling expenses and other cash expenses.
The article said that in the first quarter of 2020, Hengrui Medicine still spent 1.927 billion yuan on sales expenses, an increase of about 8% year-on-year. Based on the comparison of financial data in 2019, the company’s academic promotion and travel expenses accounted for more than 98% of sales expenses. Because Hengrui Medicine does not specify the specific amount of academic promotion and travel expenses in the quarterly report, the outside world cannot judge the company’s annual increase or decrease in academic promotion and travel expenses from January to March of this year. If Hengrui Medicine’s two expenses increase in the first quarter of this year without increasing, but in the epidemic situation, the company must give a reasonable explanation.
On the afternoon of May 12, Hengrui Pharmaceutical stated in its clarification announcement that the company’s sales expense ratio in 2019 was 36.61%. according toColor ladderAccording to statistics, the company’s sales expense ratio is ranked 85 among more than 230 companies (including API companies) in the pharmaceutical manufacturing industry of the Shanghai and Shenzhen stock markets, which is at the mid-tier of the industry. Selling expenses revealed by the company’s annual report for 2019 primarily include market expenses such as academic promotion of the company’s products, building a professional platform for innovative medicines, travel expenses and incentive expenses for capital. The amounts incurred in this period are 7,526 million yuan, 909 million yuan and 8,834.09 million yuan respectively.
Hengrui Pharmaceutical also said that the company has strictly controlled various expenses in recent years, and the sales expense ratio has decreased year after year. In the first quarter of 2020, the company’s sales activities that required on-site communication were affected by the epidemic, but sales expenses included relatively fixed expenses such as salary for sales staff, five insurances, and one of gold, office expenses, academic research and more. The increase in staff and the increase in treatment have resulted in an increase in corresponding expenses. The company implements comprehensive budget management, and strictly approves and controls the annual budget of each sales company. Each molecular company and each department prepare a monthly budget according to the progress of the work within the scope of the annual budget, and the accounts are assigned and processed by the finance department according to the request for payment within the monthly budget. The company’s past sales expenses are true, compliant, and reasonable.
Hengrui Pharmaceutical also explained other cash expenses of the company. Hengrui Pharmaceutical said that in the other cash items related to the operating activities paid for by the company in 2019, the total number of other projects amounted to 1,365 billion yuan, which mainly includes business reserves and employees used by various departments and staff of the research and development system, sales system and administrative management system. Well-being purchase loans, etc. Among them, the reserve fund for the sales system is 962 million yuan, the reserve fund for the research and development system is 304 million yuan, the reserve fund for the administrative management system is 61 million yuan, the employee welfare welfare purchase loan is 14 million yuan, and the other expense is 25 million yuan.
It is understood that cases of commercial bribery in the medical and home medicine fields have always been the focus of media attention. As a leading innovative pharmaceutical company in China, Hengrui Medicine has formed a batch of listed, developed and clinical batches. This is normal for a large amount of academic promotion, and your sales expense ratio is in the middle of the industry ranking. Typical. After the verdict was announced, it attracted media attention, deeply reflecting external anxiety and doubts about the high selling expense ratio of the entire national pharmaceutical industry.
Hengrui Pharmaceutical stated that with the deepening of reforms in the fields of national pharmaceutical, medical and medical insurance, especially the normalization and large-scale promotion of centralized national purchases of medicines, it is an inevitable trend that the national sales expenses of Medicines will decrease dramatically in the future, and the transformation of compliance will also decrease. Become the rule of thumb for national pharmaceutical companies, and cost savings will eventually benefit drug users.
Disclaimer: Content provided in a comprehensive manner by the media is derived from the media, copyright remains with the original author, please contact original author for permission to reprint. The opinions in the article only represent the author himself, not Sina’s position. If the content involves investment advice, it is for reference only and should not be used as a basis for investment. The investment is risky and you must be cautious when entering the market.
Editor-in-chief: Wang Shuai
